Puma Biotechnology, Inc. (PBYI) ended last trading session with a change of 11.86 percent. It trades at an average volume of 953.13K shares versus 1.88M shares recorded at the end of last trading session. The share price of $44.8 is at a distance of 126.95 percent from its 52-week low and down -38.86 percent versus its peak. The company has a market cap of $1.62B and currently has 36.21M shares outstanding. The share price is currently 21.63 percent versus its SMA20, 28.72 percent versus its SMA50, and 5.66 percent versus its SMA200. The stock has a weekly performance of 33.14 percent and is 45.93 percent year-to-date as of the recent close.
On March 2, 2017 Puma Biotechnology, Inc. (PBYI) announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2017. The AACR Annual Meeting will be held at the Walter E. Washington Convention Center in Washington, D.C. from April 1 to April 5.
Apr. 4, 2017, 1:00 – 5:00 p.m. EDT – Abstract 4818 (Poster): Neratinib/fulvestrant but not fulvestrant alone maintain complete tumor responses after treatment with trastuzumab + paclitaxel of mice bearing ER+/HER2+ xenografts.
L.J. Schwarz et al, Vanderbilt University Medical Center.
Marinus Pharmaceuticals, Inc. (MRNS) recently recorded 8.97 percent change and currently at $1.7 is 106.99 percent away from its 52-week low and down -74.85 percent versus its peak. It has a past 5-day performance of 24.09 percent and trades at an average volume of 1.63M shares. The stock has a 1-month performance of 41.78 percent and is 68.32 percent year-to-date as of the recent close. There were about 20.19M shares outstanding which made its market cap $34.32M. The share price is currently 22.83 percent versus its SMA20, 35.84 percent versus its SMA50, and 3.78 percent versus its SMA200.
On March 13, 2017 Marinus Pharmaceuticals, Inc. (MRNS) provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2016.
Recent Clinical & Corporate Highlights
- The new intravenous (IV) formulation of ganaxolone was successfully administered to healthy volunteers and was shown to be generally safe and well tolerated, and reached dose levels targeted for Phase 2 studies in postpartum depression (PPD), status epilepticus (SE) and other indications.
- Ganaxolone reduced seizure frequency and was generally safe and well tolerated in an on-going Phase 2 study in children with orphan, genetic disorders, including the initial treated children with CDKL5 disorder and the eleven children with PCDH19 pediatric epilepsy.
- Ganaxolone improved anxiety and hyperactivity across multiple anxiety scales in a Phase 2 clinical study in Fragile X Syndrome (FXS) children with high baseline anxiety. The FDA has granted orphan drug designation for ganaxolone to treat FXS.
- Two seasoned biotech executives were appointed to the board of directors.